Altana's Daxas Breaks from the Pack
Executive Summary
Altana's Phase III PDE-4 inhibitor Daxas has shown promising preliminary results in a second late-stage clinical trial. But class-wide concerns about the long-term safety and efficacy of this new generation of respiratory drugs-and the recent high-profile thrashing of GSK's Ariflo at the hands of an FDA advisory committee-suggest that the devil may be in the details, which aren't due to be released until May 2004. But as the competition falters, and if Daxas can remain standing, the drug could transform Altana into a truly global pharmaceutical firm while providing Pfizer with the best one-two respiratory punch in the industry.
You may also be interested in...
Boehringer's Spiriva: Advancing COPD Therapy
Boehringer Ingelheim's new COPD treatment, Spiriva, could be a blockbuster--particularly if its worldwide marketing partner Pfizer can increase diagnosis of the disease and expand COPD drugs' prescribing base from specialists to GPs. But, complicating matters for Boehringer, Pfizer--through its proposed acquisition of Pharmacia--will also market the PDE-4 inhibitor roflumilast, Altana's next-generation COPD therapy.
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
CNS IPOs Follow Broad Industry Trends
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.